Christina Trojacher
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Christina Trojacher has a total of 20 co-authors. Here are the top co-authors by number of shared publications:
- Andreas J. Kungl
Institute of Pharmaceutical Sciences, University of Graz, Schubertstraße 1, A-8010 Graz, Austria
2 shared publications - Aid Atlic
Validogen GmbH, Parkring 18, 8074, Raaba-Grambach, Austria
1 shared publication - Elisa Talker
Institute of Pharmaceutical Sciences, Karl-Franzens-University Graz, Universitätsplatz 1, A-8010 Graz, Austria
1 shared publication - Fabio Beretta
Laboratory of Molecular Immunology, Rega Institute for Medical Research, Dep. of Microbiology, Immunology and Transplantation, KU Leuven, Herestraat 49, box 1042, 3000, Leuven, Belgium
1 shared publication - Frank S. Walsh
Ossianix, Inc., Stevenage Bioscience Catalyst, Gunnels Wood Rd, Stevenage, Herts SG1 2FX, UK
1 shared publication - Johannes Almer
Institute of Pharmaceutical Sciences, Karl-Franzens-University of Graz, Schubertstrasse 1, 8010, Graz, Austria
1 shared publication
Latest Publications
- Open Access
- 26 December 2025
- Published by Elsevier in International Journal of Biological Macromolecules
- Vol. 339, 149825
Improving the in vivo activity of glycosaminoglycan-binding immunomodulatory drugs by fusion to human serum albumin
- 26 December 2025
- Published by Elsevier in International Journal of Biological Macromolecules
- Vol. 339, 149825
Open AccessImproving the in vivo activity of glycosaminoglycan-binding immunomodulatory drugs by fusion to human serum albumin
- Open Access
- 24 April 2025
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 26 (9) , 4045
A Single-Domain VNAR Nanobody Binds with High-Affinity and Selectivity to the Heparin Pentasaccharide Fondaparinux
Glycosaminoglycans (GAGs) are key ligands for proteins involved in physiological and pathological processes. Specific GAG-binding patterns are rarely identified, with the heparin pentasaccharide as an Antithrombin-III ligand being the best characterized. Generating glycan-specific antibodies is difficult due to their size, pattern dispersion, and flexibility. Single-domain variable new antigen receptors (VNAR nanobodies) from nurse sharks are highly soluble, stable, and versatile. Their unique properties suggest advantages over conventional antibodies, particularly for challenging biotherapeutic targets. Here we have used VNAR semi-synthetic phage libraries to select high-affinity fondaparinux-binding VNARs that did not show cross-reactivity with other GAG species. Competition ELISA and surface plasmon resonance identified a single fondaparinux-selective VNAR clone. This VNAR exhibited an extraordinarily stable protein fold: the beta-strands are stabilized by a robust hydrophobic network, as revealed by heteronuclear NMR. Docking fondaparinux to the VNAR structure revealed a large contact surface area between the CDR3 loop of the antibody and the glycan. Fusing the VNAR with a human Fc domain resulted in a stable product with a high affinity for fondaparinux (Kd = 9.3 × 10−8 M) that could efficiently discriminate between fondaparinux and other glycosaminoglycans. This novel glycan-targeting screening technology represents a promising therapeutic strategy for addressing GAG-related diseases.
- 24 April 2025
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 26 (9) , 4045
Open AccessA Single-Domain VNAR Nanobody Binds with High-Affinity and Selectivity to the Heparin Pentasaccharide Fondaparinux
Glycosaminoglycans (GAGs) are key ligands for proteins involved in physiological and pathological processes. Specific GAG-binding patterns are rarely identified, with the heparin pentasaccharide as an Antithrombin-III ligand being the best characterized. Generating glycan-specific antibodies is difficult due to their size, pattern dispersion, and flexibility. Single-domain variable new antigen receptors (VNAR nanobodies) from nurse sharks are highly soluble, stable, and versatile. Their unique properties suggest advantages over conventional antibodies, particularly for challenging biotherapeutic targets. Here we have used VNAR semi-synthetic phage libraries to select high-affinity fondaparinux-binding VNARs that did not show cross-reactivity with other GAG species. Competition ELISA and surface plasmon resonance identified a single fondaparinux-selective VNAR clone. This VNAR exhibited an extraordinarily stable protein fold: the beta-strands are stabilized by a robust hydrophobic network, as revealed by heteronuclear NMR. Docking fondaparinux to the VNAR structure revealed a large contact surface area between the CDR3 loop of the antibody and the glycan. Fusing the VNAR with a human Fc domain resulted in a stable product with a high affinity for fondaparinux (Kd = 9.3 × 10−8 M) that could efficiently discriminate between fondaparinux and other glycosaminoglycans. This novel glycan-targeting screening technology represents a promising therapeutic strategy for addressing GAG-related diseases.